Sunshine Biopharma Warrant Stock Performance
| SBFMW Stock | USD 0.22 0.01 4.76% |
Sunshine Biopharma holds a performance score of 13 on a scale of zero to a hundred. The entity has a beta of 2.34, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Sunshine Biopharma will likely underperform. Use Sunshine Biopharma potential upside, as well as the relationship between the accumulation distribution and price action indicator , to analyze future returns on Sunshine Biopharma.
Risk-Adjusted Performance
13 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Sunshine Biopharma Warrant are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating primary indicators, Sunshine Biopharma showed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Sunshine Biopharma expands generic drug portfolio - Investing.com | 09/26/2024 |
2 | Acquisition by Camille Sebaaly of 30000 shares of Sunshine Biopharma at 0.7635 subject to Rule 16b-3 | 10/23/2024 |
3 | Sunshine Biopharma launches generic liver drug in Canada - Investing.com | 11/22/2024 |
| Begin Period Cash Flow | 21.8 M |
Sunshine |
Sunshine Biopharma Relative Risk vs. Return Landscape
If you would invest 9.73 in Sunshine Biopharma Warrant on August 28, 2024 and sell it today you would earn a total of 12.27 from holding Sunshine Biopharma Warrant or generate 126.1% return on investment over 90 days. Sunshine Biopharma Warrant is currently producing 3.6746% returns and takes up 22.2346% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Sunshine, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Sunshine Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sunshine Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sunshine Biopharma Warrant, and traders can use it to determine the average amount a Sunshine Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1653
| Best Portfolio | Best Equity | |||
| Good Returns | SBFMW | |||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 22.23 actual daily | 96 96% of assets are less volatile |
Expected Return
| 3.67 actual daily | 73 73% of assets have lower returns |
Risk-Adjusted Return
| 0.17 actual daily | 13 87% of assets perform better |
Based on monthly moving average Sunshine Biopharma is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sunshine Biopharma by adding it to a well-diversified portfolio.
Sunshine Biopharma Fundamentals Growth
Sunshine Stock prices reflect investors' perceptions of the future prospects and financial health of Sunshine Biopharma, and Sunshine Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sunshine Stock performance.
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.13) % | ||||
| Operating Margin | (0.13) % | ||||
| Revenue | 24.09 M | ||||
| Gross Profit | 110.6 K | ||||
| EBITDA | (3.82 M) | ||||
| Net Income | (4.51 M) | ||||
| Cash And Equivalents | 40.56 M | ||||
| Cash Per Share | 1.80 X | ||||
| Total Debt | 657.71 K | ||||
| Debt To Equity | 8.98 % | ||||
| Current Ratio | 85.09 X | ||||
| Book Value Per Share | 12.52 X | ||||
| Cash Flow From Operations | (8.78 M) | ||||
| Earnings Per Share | (2.21) X | ||||
| Total Asset | 27.35 M | ||||
| Retained Earnings | (63.91 M) | ||||
| Working Capital | 19.34 M | ||||
About Sunshine Biopharma Performance
Evaluating Sunshine Biopharma's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Sunshine Biopharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Sunshine Biopharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 132.87 | 141.65 | |
| Return On Tangible Assets | (0.17) | (0.18) | |
| Return On Capital Employed | (0.22) | (0.21) | |
| Return On Assets | (0.16) | (0.17) | |
| Return On Equity | (0.21) | (0.20) |
Things to note about Sunshine Biopharma performance evaluation
Checking the ongoing alerts about Sunshine Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sunshine Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sunshine Biopharma is way too risky over 90 days horizon | |
| Sunshine Biopharma has some characteristics of a very speculative penny stock | |
| Sunshine Biopharma appears to be risky and price may revert if volatility continues | |
| Sunshine Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 24.09 M. Net Loss for the year was (4.51 M) with profit before overhead, payroll, taxes, and interest of 110.6 K. | |
| Sunshine Biopharma Warrant has accumulated about 40.56 M in cash with (8.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.8, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from news.google.com: Sunshine Biopharma launches generic liver drug in Canada - Investing.com |
- Analyzing Sunshine Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sunshine Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Sunshine Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sunshine Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sunshine Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sunshine Biopharma's stock. These opinions can provide insight into Sunshine Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Sunshine Stock Analysis
When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.